Entrectinib in patients with advanced or metastatic NTRK fusion- positive solid tumours: integrated analysis of three phase 1-2 trials (vol 21, pg 271, 2020)

被引：0
|
作者：
Doebele, R. C.
Drilon, A.
Paz-Ares, L.
机构：
来源：
LANCET ONCOLOGY | 2020年 / 21卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E372 / E372
页数：1
相关论文
共 50 条
  • [41] Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naive and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)
    Besse, B.
    Springfeld, C.
    Baik, C.
    Hervieu, A.
    Solomon, B.
    Moreno, V.
    Bazhenova, L.
    Goto, K.
    Kim, Y. C.
    Lu, S.
    Sun, M.
    Trone, D.
    Thamake, S.
    Cho, B. C.
    De langen, A.
    Popat, S.
    Wolf, J.
    Moro-Sibilot, D.
    Fang, J.
    Drilon, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S75 - S76
  • [42] Entrectinib in neurotrophic receptor tyrosine kinase fusion-positive (NTRK-fp) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001
    Paz-Ares, L.
    Doebel, R. C.
    Farago, A. F.
    Liu, S.
    Chawla, S. P.
    Tosi, D.
    Blakely, C. M.
    Krauss, J. C.
    Sigal, D.
    Bazhenova, L.
    John, T.
    Besse, B.
    Wolf, J.
    Seto, T.
    Chow-Maneval, E.
    Ye, C.
    Simmons, B.
    Demetri, G. D.
    PNEUMOLOGIE, 2020, 74 : S128 - S129
  • [43] Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid (vol 21, pg 3497, 2013)
    von Moos, Roger
    Body, Jean-Jacques
    Egerdie, Blair
    Stopeck, Alison
    Brown, Janet E.
    Damyanov, Danail
    Fallowfield, Lesley J.
    Marx, Gavin
    Cleeland, Charles S.
    Patrick, Donald L.
    Palazzo, Felipe G.
    Qian, Yi
    Braun, Ada
    Chung, Karen
    SUPPORTIVE CARE IN CANCER, 2014, 22 (08) : 2309 - 2310
  • [44] Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials (vol 108, pg 196, 2020)
    Chen, Dawei
    Verma, Vivek
    Patel, Roshal R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (02): : 623 - 623
  • [45] Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
    Geoerger, Birgit
    Kang, Hyoung Jin
    Yalon-Oren, Michal
    Marshall, Lynley V.
    Vezina, Catherine
    Pappo, Alberto
    Laetsch, Theodore W.
    Petrilli, Antonio S.
    Ebinger, Martin
    Toporski, Jacek
    Glade-Bender, Julia
    Nicholls, Wayne
    Fox, Elizabeth
    DuBois, Steven G.
    Macy, Margaret E.
    Cohn, Susan L.
    Pathiraja, Kumudu
    Diede, Scott J.
    Ebbinghaus, Scot
    Pinto, Navin
    LANCET ONCOLOGY, 2020, 21 (01): : 121 - 133
  • [46] Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06) (vol 21, pg 421, 2017)
    Kimura, Yutaka
    Fujii, Masashi
    Masuishi, Toshiki
    Nishikawa, Kazuhiro
    Kunisaki, Chikara
    Matsusaka, Satoshi
    Segawa, Yoshihiko
    Nakamura, Masato
    Sasaki, Kinro
    Nagao, Narutoshi
    Hatachi, Yukimasa
    Yuasa, Yasuhiro
    Asami, Shinya
    Takeuchi, Masahiro
    Furukawa, Hiroshi
    Nakajima, Toshifusa
    GASTRIC CANCER, 2018, 21 (03) : 428 - 428
  • [47] BIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Kudla, A.
    Adiwijaya, B.
    Paragas, V.
    Richards, D.
    Braiteh, F.
    Garcia, A. A.
    Denlinger, C. S.
    Conkling, P.
    Edenfield, W. J.
    Anthony, S.
    Hellerstedt, B.
    Raju, R.
    Becerra, C.
    Harb, W.
    Smith, D.
    Kawash, K.
    Frye, S.
    McDonagh, C. F.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Double-Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftarole Fosamil versus Ceftriaxone in Patients with Community-Acquired Pneumonia (vol 51, pg 1395, 2010)
    File, T. M.
    Low, D. E.
    Eckburg, P. B.
    Talbot, G. H.
    Friedland, H. D.
    Lee, J.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (07) : 967 - 967
  • [49] Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study (vol 20, pg 1681, 2019)
    Ahn, M-J
    Han, J-Y
    Lee, K. H.
    LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
  • [50] Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study (vol 21, pg 1478, 2020)
    Guo, C.
    Chenard-Poirier, M.
    Roda, D.
    LANCET ONCOLOGY, 2021, 22 (02): : E42 - E42
12345